搜索结果
疾病ID:TCMBANKDI009160
疾病名:Machado-Joseph Disease
MeSH_Name:Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases
HPO_Name:-
UMLS_Name:Disease or Syndrome
DO_Name:genetic disease; disease of anatomical entity
疾病类型:disease
DisGeNET_Link:C0024408
MeSH_Link:C16; C10
HPO_Link:-
UMLS_Link:T047
DO_Link:DOID:630; DOID:7
HERB_ID:-
疾病对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
疾病对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN058205 | trans-resveratrol | (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene | C14H12O3 | 228.24 g/mol | C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
疾病对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 |
|---|
| TCMBANKGE015115 | GEMIN4 | HC56; HCAP1; HHRF-1; NEDMCR; p97 | gem nuclear organelle associated protein 4 |
| TCMBANKGE010552 | PLEKHG4 | ARHGEF44; PRTPHN1; SCA4 | pleckstrin homology and RhoGEF domain containing G4 |
| TCMBANKGE011415 | ASIC1 | ACCN2; ASIC; BNaC2 | acid sensing ion channel subunit 1 |
| TCMBANKGE002758 | HSPB8 | CMT2L; DHMN2; E2IG1; H11; HMN2; HMN2A; HSP22 | heat shock protein family B (small) member 8 |
| TCMBANKGE004058 | UBB | HEL-S-50 | ubiquitin B |
| TCMBANKGE012556 | CFDP1 | BCNT; BUCENTAUR; CENP-29; CP27; SWC5; Yeti; p97 | craniofacial development protein 1 |
| TCMBANKGE005402 | CST3 | ARMD11; HEL-S-2 | cystatin C |
| TCMBANKGE001132 | BAX | BCL2L4 | BCL2 associated X, apoptosis regulator |
| TCMBANKGE009047 | CA11 | CA-RP; CA-RP II; CA-XI; CARP-2; CARPX1 | carbonic anhydrase 11 |
| TCMBANKGE000426 | PPP1R1B | DARPP-32; DARPP32 | protein phosphatase 1 regulatory inhibitor subunit 1B |
| TCMBANKGE011252 | EIF4G2 | AAG1; DAP5; NAT1; P97 | eukaryotic translation initiation factor 4 gamma 2 |
| TCMBANKGE013893 | IVL | - | involucrin |
| TCMBANKGE008359 | CA8 | CA-RP; CA-VIII; CALS; CAMRQ3; CARP | carbonic anhydrase 8 |
| TCMBANKGE001076 | SOD2 | GClnc1; IPO-B; IPOB; MNSOD; MVCD6; Mn-SOD | superoxide dismutase 2 |
| TCMBANKGE013383 | VCP | CDC48; TERA; p97 | valosin containing protein |
| TCMBANKGE007654 | PICK1 | PICK; PRKCABP | protein interacting with PRKCA 1 |
| TCMBANKGE007365 | IGFALS | ACLSD; ALS | insulin like growth factor binding protein acid labile subunit |
| TCMBANKGE000526 | ATXN1 | ATX1; D6S504E; SCA1 | ataxin 1 |
| TCMBANKGE006928 | CTRL | CTRL1 | chymotrypsin like |
| TCMBANKGE012856 | ATXN3 | AT3; ATX3; JOS; MJD; MJD1; SCA3 | ataxin 3 |
| TCMBANKGE009229 | MSC | ABF-1; ABF1; MYOR; bHLHa22 | musculin |
| TCMBANKGE001074 | ATM | AT1; ATA; ATC; ATD; ATDC; ATE; TEL1; TELO1 | ATM serine/threonine kinase |
| TCMBANKGE008499 | CAST | BS-17; PLACK | calpastatin |
| TCMBANKGE001192 | HCRT | NRCLP1; OX; PPOX | hypocretin neuropeptide precursor |
| TCMBANKGE001061 | CDK5 | LIS7; PSSALRE | cyclin dependent kinase 5 |
| TCMBANKGE000031 | DNMT3A | DNMT3A2; HESJAS; M.HsaIIIA; TBRS | DNA methyltransferase 3 alpha |
| TCMBANKGE000298 | SOD1 | ALS; ALS1; HEL-S-44; IPOA; SOD; STAHP; hSod1; homodimer | superoxide dismutase 1 |
| TCMBANKGE009977 | SPTBN2 | GTRAP41; SCA5; SCAR14 | spectrin beta, non-erythrocytic 2 |
| TCMBANKGE012155 | SLC6A3 | DAT; DAT1; PKDYS; PKDYS1 | solute carrier family 6 member 3 |
| TCMBANKGE005288 | PDYN | ADCA; PENKB; SCA23 | prodynorphin |
| TCMBANKGE005712 | DNAJB1 | HSPF1; Hdj1; Hsp40; RSPH16B; Sis1 | DnaJ heat shock protein family (Hsp40) member B1 |
| TCMBANKGE006653 | PNKP | AOA4; CMT2B2; EIEE10; MCSZ; PNK | polynucleotide kinase 3'-phosphatase |
| TCMBANKGE002183 | SLC22A2 | 2021/10/2 | solute carrier family 22 member 2 |
| TCMBANKGE010269 | RANGAP1 | Fug1; RANGAP; SD | Ran GTPase activating protein 1 |
| TCMBANKGE000114 | PLA2G6 | CaI-PLA2; GVI; INAD1; IPLA2-VIA; NBIA2; NBIA2A; NBIA2B; PARK14; PLA2; PNPLA9; iPLA2; iPLA2beta | phospholipase A2 group VI |
| TCMBANKGE009107 | ACY3 | ACY-3; HCBP1 | aminoacylase 3 |
| TCMBANKGE004772 | PDIK1L | CLIK1L; STK35L2 | PDLIM1 interacting kinase 1 like |
| TCMBANKGE000655 | Lamp2 | CD107b; LGP-B; Lamp II; Lamp-2; Lamp-2a; Lamp-2b; Lamp-2c; Mac3 | lysosomal-associated membrane protein 2 |
| TCMBANKGE002901 | TDO2 | HYPTRP; TDO; TO; TPH2; TRPO | tryptophan 2,3-dioxygenase |
| TCMBANKGE001037 | MMP2 | CLG4; CLG4A; MMP-2; MMP-II; MONA; TBE-1 | matrix metallopeptidase 2 |
| TCMBANKGE013653 | TSHZ1 | CAA; NY-CO-33; SDCCAG33; TSH1 | teashirt zinc finger homeobox 1 |
| TCMBANKGE001198 | BECN1 | ATG6; VPS30; beclin1 | beclin 1 |
| TCMBANKGE000271 | APOE | AD2; APO-E; ApoE4; LDLCQ5; LPG | apolipoprotein E |
| TCMBANKGE006565 | NPY | PYY4 | neuropeptide Y |
| TCMBANKGE000443 | TBP | GTF2D; GTF2D1; HDL4; SCA17; TFIID | TATA-box binding protein |
| TCMBANKGE001126 | NFE2L2 | HEBP1; IMDDHH; NRF2; Nrf-2 | nuclear factor, erythroid 2 like 2 |
| TCMBANKGE005688 | ACP1 | HAAP; LMW-PTP; LMWPTP | acid phosphatase 1 |
| TCMBANKGE000842 | SLC18A2 | PKDYS2; SVAT; SVMT; VAT2; VMAT2 | solute carrier family 18 member A2 |
| TCMBANKGE011771 | CUL1 | - | cullin 1 |
| TCMBANKGE002699 | TH | DYT14; DYT5b; TYH | tyrosine hydroxylase |
| TCMBANKGE003746 | CREBBP | CBP; KAT3A; MKHK1; RSTS; RSTS1 | CREB binding protein |
| TCMBANKGE013760 | SERPINA3 | AACT; ACT; GIG24; GIG25 | serpin family A member 3 |
| TCMBANKGE007797 | KITLG | DCUA; DFNA69; FPH2; FPHH; KL-1; Kitl; MGF; SCF; SF; SHEP7; SLF | KIT ligand |
| TCMBANKGE013337 | GSTM2 | GST4; GSTM; GSTM2-2; GTHMUS | glutathione S-transferase mu 2 |
| TCMBANKGE004266 | AR | AIS; AR8; DHTR; HUMARA; HYSP1; KD; NR3C4; SBMA; SMAX1; TFM | androgen receptor |
| TCMBANKGE000730 | HSPB2 | HSP27; Hs.78846; LOH11CR1K; MKBP | heat shock protein family B (small) member 2 |
| TCMBANKGE002600 | FUS | ALS6; ETM4; FUS1; HNRNPP2; POMP75; TLS | FUS RNA binding protein |
| TCMBANKGE001154 | CREB1 | CREB; CREB-1 | cAMP responsive element binding protein 1 |
| TCMBANKGE000169 | BBC3 | JFY-1; JFY1; PUMA | BCL2 binding component 3 |
| TCMBANKGE000748 | PLA2G2A | MOM1; PLA2; PLA2B; PLA2L; PLA2S; PLAS1; sPLA2 | phospholipase A2 group IIA |
| TCMBANKGE005617 | SNAP29 | CEDNIK; SNAP-29 | synaptosome associated protein 29 |
| TCMBANKGE004506 | SKP1 | EMC19; OCP-II; OCP2; SKP1A; TCEB1L; p19A | S-phase kinase associated protein 1 |
| TCMBANKGE000301 | SLC2A1 | CSE; DYT17; DYT18; DYT9; EIG12; GLUT; GLUT-1; GLUT1; GLUT1DS; HTLVR; PED; SDCHCN | solute carrier family 2 member 1 |
| TCMBANKGE008229 | SYBU | GOLSYN; OCSYN; SNPHL | syntabulin |
| TCMBANKGE006071 | PTPN13 | FAP-1; PNP1; PTP-BAS; PTP-BL; PTP1E; PTPL1; PTPLE; hPTP1E | protein tyrosine phosphatase non-receptor type 13 |
| TCMBANKGE005810 | HTT | HD; IT15; LOMARS | huntingtin |
| TCMBANKGE002763 | RMDN2 | BLOCK18; FAM82A; FAM82A1; PRO34163; PYST9371; RMD-2; RMD2; RMD4 | regulator of microtubule dynamics 2 |
| TCMBANKGE013318 | PLA2G1B | PLA2; PLA2A; PPLA2 | phospholipase A2 group IB |
| TCMBANKGE000823 | GABPA | E4TF1-60; E4TF1A; NFT2; NRF2; NRF2A; RCH04A07 | GA binding protein transcription factor subunit alpha |
| TCMBANKGE010416 | PSMD2 | P97; RPN1; S2; TRAP2 | proteasome 26S subunit, non-ATPase 2 |
| TCMBANKGE000934 | GFAP | ALXDRD | glial fibrillary acidic protein |
| TCMBANKGE000041 | IRF1 | IRF-1; MAR | interferon regulatory factor 1 |
| TCMBANKGE003046 | AVP | ADH; ARVP; AVP-NPII; AVRP; VP | arginine vasopressin |
| TCMBANKGE002521 | CACNA1A | APCA; BI; CACNL1A4; CAV2.1; EA2; EIEE42; FHM; HPCA; MHP; MHP1; SCA6 | calcium voltage-gated channel subunit alpha1 A |
| TCMBANKGE004291 | TK2 | MTDPS2; MTTK; PEOB3; SCA31 | thymidine kinase 2 |
| TCMBANKGE013449 | ARSB | ASB; G4S; MPS6 | arylsulfatase B |
| TCMBANKGE000806 | HSPA4 | APG-2; HEL-S-5a; HS24/P52; HSPH2; RY; hsp70; hsp70RY | heat shock protein family A (Hsp70) member 4 |
| TCMBANKGE000643 | TTR | ATTR; CTS; CTS1; HEL111; HsT2651; PALB; TBPA | transthyretin |
| TCMBANKGE010609 | UBQLN2 | ALS15; CHAP1; DSK2; HRIHFB2157; N4BP4; PLIC2 | ubiquilin 2 |
| TCMBANKGE007230 | FXN | CyaY; FA; FARR; FRDA; X25 | frataxin |
| TCMBANKGE012217 | MSI1 | - | musashi RNA binding protein 1 |
| TCMBANKGE007298 | TOR1A | DQ2; DYT1 | torsin family 1 member A |
| TCMBANKGE014675 | RORA | IDDECA; NR1F1; ROR1; ROR2; ROR3; RZR-ALPHA; RZRA | RAR related orphan receptor A |
| TCMBANKGE003545 | KPNA3 | IPOA4; SRP1; SRP1gamma; SRP4; hSRP1 | karyopherin subunit alpha 3 |
| TCMBANKGE003852 | LY6E | RIG-E; RIGE; SCA-2; SCA2; TSA-1 | lymphocyte antigen 6 family member E |
| TCMBANKGE008929 | EFNA3 | EFL2; EPLG3; Ehk1-L; LERK3 | ephrin A3 |
| TCMBANKGE002053 | AICDA | AID; ARP2; CDA2; HEL-S-284; HIGM2 | activation induced cytidine deaminase |
| TCMBANKGE005550 | GABARAP | ATG8A; GABARAP-a; MM46 | GABA type A receptor-associated protein |
| TCMBANKGE011954 | TARDBP | ALS10; TDP-43 | TAR DNA binding protein |
| TCMBANKGE010359 | DMPK | DM; DM1; DM1PK; DMK; MDPK; MT-PK | DM1 protein kinase |
| TCMBANKGE000373 | ATG12 | APG12; APG12L; FBR93; HAPG12 | autophagy related 12 |
| TCMBANKGE014572 | TPO | MSA; TDH2A; TPX | thyroid peroxidase |
| TCMBANKGE009876 | HMBS | PBG-D; PBGD; PORC; UPS | hydroxymethylbilane synthase |
| TCMBANKGE001773 | DNMT3L | - | DNA methyltransferase 3 like |
| TCMBANKGE001172 | HSP90AA1 | EL52; HEL-S-65p; HSP86; HSP89A; HSP90A; HSP90N; HSPC1; HSPCA; HSPCAL1; HSPCAL4; HSPN; Hsp103; Hsp89; Hsp90; LAP-2; LAP2 | heat shock protein 90 alpha family class A member 1 |
| TCMBANKGE001340 | ATG16L2 | ATG16B; WDR80 | autophagy related 16 like 2 |
| TCMBANKGE001001 | SNCA | NACP; PARK1; PARK4; PD1 | synuclein alpha |
| TCMBANKGE000797 | HSPB1 | CMT2F; HEL-S-102; HMN2B; HS.76067; HSP27; HSP28; Hsp25; SRP27 | heat shock protein family B (small) member 1 |
| TCMBANKGE007993 | RAB1A | RAB1; YPT1 | RAB1A, member RAS oncogene family |
| TCMBANKGE007742 | HSPB3 | DHMN2C; HMN2C; HSPL27 | heat shock protein family B (small) member 3 |
| TCMBANKGE003539 | PAH | PH; PKU; PKU1 | phenylalanine hydroxylase |
| TCMBANKGE010103 | OPTN | ALS12; FIP2; GLC1E; HIP7; HYPL; NRP; TFIIIA-INTP | optineurin |
| TCMBANKGE014544 | ELAVL3 | HUC; HUCL; PLE21 | ELAV like RNA binding protein 3 |
| TCMBANKGE000175 | FBXW7 | AGO; CDC4; FBW6; FBW7; FBX30; FBXO30; FBXW6; SEL-10; SEL10; hAgo; hCdc4 | F-box and WD repeat domain containing 7 |
| TCMBANKGE000075 | IL1RN | DIRA; ICIL-1RA; IL-1RN; IL-1ra; IL-1ra3; IL1F3; IL1RA; IRAP; MVCD4 | interleukin 1 receptor antagonist |
滇IICP备16009434号-1 |
Dai SX Lab